Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.

ABSTRACT:

Background

Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase inhibitors (HDACi) are anticancer agents targeting epigenetic regulation of gene expression and are in clinical development in MM.

Methods

To create a score predicting HDACi efficacy, five MM cell lines were treated with trichostatin A (TSA) and gene expression profiles were determined.

Results

The expression of 95 genes was found to be upregulated by TSA, using paired supervised analysis with Significance Analysis of Microarrays software. Thirty-seven of these 95

SUBMITTER: Moreaux J 

PROVIDER: S-EPMC3739014 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature